Skip to main content

Advertisement

SpringerLink
Log in

Biological Therapy-Induced Systemic Vasculitis

  • Vasculitis (LR Espinoza, Section Editor)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

The use of biologics has been associated with the paradoxical development of biologics-induced autoimmune diseases. The purpose of this review was to describe the key immunopathogenic mechanisms involved in the development of these conditions, and to discuss the clinical and laboratory characteristics usually described in the medical literature, reviewing case reports as well as records on national biologic therapies (BIOGEAS, RABBIT, BSRBR-RA, BIOBADAVEN). More than 200 cases have so far been reported, all of them diagnosed on the basis of the histopathology or meeting the ACR/Chapel Hill criteria. Over 75 % of the cases were females with a mean age of 48 ± 5 years. More than 50 % had rheumatoid arthritis. Most of the biologics-associated vasculitis developed in 90 ± 31 days. Complete resolution in almost 75 % of the cases was observed upon treatment discontinuation; however, steroid therapy was indicated for all patients and one death was recorded. The use of cyclophosphamide, rituximab or plasma exchange was reserved for the most severe cases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Finsterbusch M, Voisin MB, Beyrau M, et al. Neutrophils recruited by chemoattractants in vivo induce microvascular plasma protein leakage through secretion of TNF. J Exp Med. 2014;211:1307–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Zweemer AJ, Toraskar J, Heitman LH, et al. Bias in chemokine receptor signaling. Trends Immunol. 2014;35:243–52.

    Article  CAS  PubMed  Google Scholar 

  3. Jarrot PA, Kaplanski G. Anti-TNF-alpha therapy and systemic vasculitis. Mediat Inflamm. 2014;2014:493593. doi:10.1155/2014/493593.

    Article  Google Scholar 

  4. Chakravarty K, Ong VH, Denton CP. Secondary vasculitis in autoimmune connective tissue diseases. Curr Opin Rheumatol. 2016;28(1):60–5. Excellent review of the immunopathology of secondary vasculitis.

    Article  CAS  PubMed  Google Scholar 

  5. Danning CL, Illei GG, Boumpas DT. Vasculitis associated with primary rheumatologic diseases. Curr Opin Rheumatol. 1998;10:58–65.

    Article  CAS  PubMed  Google Scholar 

  6. Jennette JC, Falk RJ, Bacon PA, et al. Revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2012;65(1):1–11.

    Article  Google Scholar 

  7. Li JL, Lim CH, Tay FW, et al. Neutrophils self-regulate immune complex-mediated cutaneous inflammation through CXCL2. J Invest Dermatol. 2016;136(2):416–24. doi:10.1038/JID.2015.410.

    Article  CAS  PubMed  Google Scholar 

  8. Bartels CM, Bridges AJ. Rheumatoid vasculitis: vanishing menace or target for new treatments? Curr Rheumatol Rep. 2010;12(6):414–9. doi:10.1007/s11926-010-0130-1.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Chung SA, Xie G, Roshandel D, et al. Meta-analysis in granulomatosis with polyangiitis reveals shared susceptibility loci with rheumatoid arthritis. Arthritis Rheum. 2012;64(10):3463–71. doi:10.1002/art.34496.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Carr EJ, Niederer HA, Williams J, et al. Confirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitis. BMC Med Genet. 2009;10:12. doi:10.1186/1471-2350-10-121. An excellent study which demonstrated genetic susceptibility vasculitis and rheumatoid arthritis.

    Google Scholar 

  11. Grau RG. Drug-induced vasculitis: new insights and a changing lineup of suspects. Curr Rheumatol Rep. 2015;17:71. Excellent review of vasculitis secondary to drugs.

    Article  PubMed  Google Scholar 

  12. Kessenbrock K, Krumbholz M, Schonermarck U, Back W, Gross WL, Werb Z, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009;15:623–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA, et al. Anti‐tumor necrosis factor‐alpha therapy‐induced vasculitis: case series. J Rheumatol. 2003;30:2287–91.

    PubMed  Google Scholar 

  14. Mariani N, So A, Aubry-Rozier B. Two cases of Takayasu's arteritis occurring under anti-TNF therapy. Joint Bone Spine. 2013;80(2):211–3.

    Article  PubMed  Google Scholar 

  15. Cestelli V, Spinella A, Campomori F, Esposito C, Ciaffi S, Sandri G, et al. Large vessel vasculitis occurring in rheumatoid arthritis patient under anti-TNF therapy. Case Rep Med. 2014;2014:624184.

    PubMed  PubMed Central  Google Scholar 

  16. Sokumbi O, Wetter DA, Makol A, Warrington KJ. Vasculitis associated with tumor necrosis factor-α inhibitors. Mayo Clin Proc. 2012;87(8):739–45.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA. BIOGEAS Study Group Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev. 2010;9(3):188–93. Report of a European study group with extensive experience in vasculitis and very well positioned in the rheumatology community.

    Article  CAS  PubMed  Google Scholar 

  18. Gutierrez-Gonzalez LA. Efficacy and safety of biological DMARDs. BIOBADAVEN. Paper presented at the 7th International Symposium of Rheumatology. Eurobuilding Hotel, Caracas, 23-24 April 2015.

  19. Jani M, Dixon W, Kearsley-Fleet L, Bruce I, Chinoy H, Barton A, et al. Risk and characteristics of drug induced vasculitis in patients exposed to tumor necrosis factor α inhibitor therapy: results from BSRBR. Ann Rheum Dis. 2015;74(Suppl2):787. First and only prospective study to compare synthetic and biological DMARDs and the risk of vasculitis.

    Google Scholar 

  20. Cleynen I et al. Characteristics of skin lesions associated with anti–tumor necrosis factor therapy in patients with inflammatory bowel disease. A cohort study. Ann Intern Med. 2016;164:10–22. Important skin lesions revision of post-anti-TNF therapy in patients with inflammatory bowel disease.

    Article  PubMed  Google Scholar 

  21. Inafuku H, Kasem Khan MA, Nagata T, Nonaka S. Cutaneous ulcerations following subcutaneous interferon beta injection to a patient with multiple sclerosis. J Dermatol. 2004;31(8):671–7.

    Article  PubMed  Google Scholar 

  22. Sobaci G, Erdem U, Durukan AH, Erdurman C, Bayer A, Köksal S, et al. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments. Ophthalmology. 2010;117(7):1430–5. doi:10.1016/j.ophtha.2009.11.022.

    Article  PubMed  Google Scholar 

  23. Ippoliti G, Paulli M, Lucioni M, Lauriola M, D'Armini AM. Leukocytoclastic vasculitis as a complication of recombinant granulocyte colony-stimulating factor therapy in a heart transplant patient. Case Rep Transplant. 2014;2014:160407. doi:10.1155/2014/160407.

    PubMed  PubMed Central  Google Scholar 

  24. Sene D, Ghillani-Dalbin P, Amoura Z, Musset L, Cacoub P. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum. 2009;60:3848–55.

    Article  CAS  PubMed  Google Scholar 

  25. Takase K, Horton SC, Ganesha A, Das S, McHugh A, Emery P, et al. What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort. Ann Rheum Dis. 2014;73(9):1695–9.

    Article  CAS  PubMed  Google Scholar 

  26. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F. The effect of TNF alpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus. 2005;14(12):931–7. doi:10.1191/0961203305lu2240rr.

    Article  PubMed  Google Scholar 

  27. Scarpato S, Atzeni F, Sarzi-Puttini P, et al. Pain management in cryoglobulinaemic syndrome from Italian Group for Study of Cryoglobulinaemia (GISC). Best Pract Res Clin Rheumatol. 2015;29(1):77–89.

    Article  PubMed  Google Scholar 

  28. Guillevin L, Pagnoux C. Indication for plasma exchange for systemic necrotizing vasculidities. Transfus Apher Sci. 2007;36(2):179–85.

    Article  PubMed  Google Scholar 

  29. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis (RAVE-INT Group). N Engl J Med. 2010;363:221–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Jones RB, Cohen Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. For the European Vasculitis Study Group (EUVAS). N Engl J Med. 2010;363:211–20.

    Article  CAS  PubMed  Google Scholar 

  31. Dumoitier N, Terrier B, London J, Lofek S, Mouthon L. Implication of B lymphocytes in the pathogenesis of ANCA-associated vasculitides. Autoimmun Rev. 2015;14(11):996–1004.

    Article  CAS  PubMed  Google Scholar 

  32. Shah S, Hruskova Z, Segelmark M, Morgan MD, Hogan J, Lee SK, et al. Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab. Am J Nephrol. 2015;41(4-5):296–301. doi:10.1159/000431336.

    Article  CAS  PubMed  Google Scholar 

  33. Charles F, Henderson CF, Seo P. Biologic agents in systemic vasculitis. Int J Clin Rheumatol. 2011;6(4):453–62.

    Article  Google Scholar 

  34. Huugen D, Cohen Tervaert JW, Heeringa P. TNF-alpha bioactivity-inhibiting therapy in ANCA-associated vasculitis: clinical and experimental considerations. Clin J Am Soc Nephrol. 2006;1:1100–7.

    Article  CAS  PubMed  Google Scholar 

  35. Molloy ES, Langford CA, Clark TJ, Gota CE, Hoffman GS. Anti-tumor necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis. 2008;67(11):1567–9.

    Article  CAS  PubMed  Google Scholar 

  36. Schmidt J, Kermani TA, Bacani KA, Crowson CS, Matteson EL, Warrington KJ. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term follow-up. Arthritis Care Res. 2012;64(7):1079–83.

    Google Scholar 

  37. Tatò F, Rieger J, Hoffmann U. Refractory Takayasu's arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab. Int Angiol. 2005;24(3):304–7.

    PubMed  Google Scholar 

  38. Dalén J, Svedbom A, Black CM, Lyu R, Ding Q, Sajjan S, et al. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence. Rheumatol Int. 2016.

Download references

Author information

Authors and Affiliations

  1. Centro Nacional de Enfermedades Reumáticas (CNER), Hospital Universitario de Caracas, HUC-UCV, Hospital Universitario de Caracas, Los Chaguaramos, Ciudad Universitaria, UCV, Caracas, 1020, Venezuela

    Luis Arturo Gutiérrez-González

Authors
  1. Luis Arturo Gutiérrez-González
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luis Arturo Gutiérrez-González.

Ethics declarations

Conflicts of Interest

LAGG declares that he has no conflicts of interests.

Human and Animal Rights and Informed Consent

This article does not contain any information derived directly from human or animal subjects.

Additional information

This article is part of the Topical Collection on Vasculitis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gutiérrez-González, L.A. Biological Therapy-Induced Systemic Vasculitis. Curr Rheumatol Rep 18, 39 (2016). https://doi.org/10.1007/s11926-016-0588-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-016-0588-6

Keywords

Search

Navigation